Navigation Links
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Date:11/2/2007

More About the REPEAT Study

Enrolling 950 patients from Europe, North America and Latin America, REPEAT (REtreatment with PEgasys in pATients Not Responding to Peg-Intron Therapy) was designed to explore whether intensified treatment with a higher fixed-dose induction of PEGASYS in combination with COPEGUS and/or longer treatment duration may increase treatment success rates in patients who didn't respond to at least twelve weeks of Peg-Intron/ribavirin combination therapy. Patients were randomized 2:1:1:2 to one of four regimens:

-- Patients in arms A (n=318) and B (n=158) received PEGASYS 360 mcg/week

for 12 weeks, followed by 180 mcg/week for a further 60 or 36 weeks,

respectively

-- Patients in arms C (n=158) and D (n=316) received PEGASYS 180 mcg/week

for 72 or 48 weeks, respectively

-- All patients received COPEGUS (1,000/1,200 mg/day) in combination with

PEGASYS

Results showed:

-- The primary endpoint was met: SVR, defined by undetectable hepatitis C

virus RNA in the blood six months after the end of treatment, was

significantly higher for arm A (16 percent) compared to arm D (nine

percent)

-- A pooled analysis of the 72-week arms vs. the 48-week arms showed that

72 weeks of treatment had the biggest impact on success of treatment,

with a doubling of SVR rate compared to 48 weeks (16 percent vs. eight

percent). A pooled analysis of the induction dose arms vs. standard

dose arms showed that treatment with higher fixed-dose induction for

this difficult-to-treat patient population did not provide significant

additional benefit

-- Response at 12 weeks was a strong predictor of successful treatment

-- Of patients whose virus was undetectable after 12 weeks of therapy,

57 percent in the 72-week arms went on to achieve treatment success

(by comparison, among patient
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Two mass spectrometry technologies ... as their effectiveness is established, according to ... Information says that while mass spectrometry (mass ... tool in proteomic biomarker discovery and validation, ... traditional techniques has struggled to elucidate molecular ...
(Date:2/26/2015)... RnRMarketResearch.com adds Corneal Ulcers ... to its store. This report p provides an ... The report "Corneal Ulcers - Pipeline Review, H2 2014" ... Corneal Ulcers. Corneal Ulcers are primarily result of ... infections & fungal infections. The symptoms of the ...
(Date:2/26/2015)... , Feb. 26, 2015  AbbVie (NYSE: ... abstracts of studies in its neuroscience and oncology ... the 67 th American Academy of Neurology ... , from April 18-25. The accepted abstracts feature ... in addition to investigational treatments in AbbVie,s pipeline. ...
Breaking Medicine Technology:Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7
... Utah, May 3, 2011 Healthcare workers now have the ... take precautions to better protect themselves, and share information and ... BD Medical, a segment of BD (Becton, Dickinson and Company) ... The BD Making Safety Safer(SM) program will provide nurses ...
... GenVec, Inc. (Nasdaq: GNVCD) announced that it will release financial ... Monday, May 9, 2011 after market close.  GenVec will hold ... 10, 2011 to discuss the company,s first quarter financial results ... live conference call, please dial 877-558-0567 (U.S. or Canada) or ...
Cached Medicine Technology:Resource Now Available to Help Clinicians Reduce Risk of Blood Exposure from Short Peripheral IV Catheter Insertion 2Resource Now Available to Help Clinicians Reduce Risk of Blood Exposure from Short Peripheral IV Catheter Insertion 3GenVec to Host First Quarter 2011 Earnings Call and Webcast 2
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
(Date:2/28/2015)... 28, 2015 The Classic Denture ... a new special. Throughout all of March patients ... , This service can help overall mouth ... pain. Patients may notice certain symptoms that suggest the ... These symptoms include: , 1.    Pain, clicking, and popping in ...
(Date:2/28/2015)... 28, 2015 A study out of ... gene therapy procedure for the treatment of a hereditary ... Authored by Dr. Robert MacLaren, professor of ... the Lancet Medical Journal on January 16, 2014 , ... rare genetic disorder that mostly affects men and leads ...
(Date:2/28/2015)... Beach, CA (PRWEB) February 28, 2015 ... needs of Central Coast area residents, recently announced a ... System. It’s a treatment option for new and ... kick off 2015 with a bright, white smile, Dr. ... discounted price of $299, marked down from the regular ...
(Date:2/28/2015)... 28, 2015 On Thursday, February 26th, Forbes ... Easy For Scammers To Steal Your Data , which stresses ... hands on a DIY phishing kit, or any kind of ... on another important point about how everyone’s cyber security is ... implemented, “like compromising legitimate content management systems or blogs in ...
Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4
... and more complications later, studies find , , MONDAY, Oct. ... arthritis face twice the risk of a heart attack, ... to have more heart-related complications, new research says. ... which causes the lower chambers of the heart to ...
... written and verbal instructions on the proper way to ... to suffer the serious gastrointestinal and brain bleeding problems ... to new research from the University of Pennsylvania School ... Journal of General Internal Medicine , also shows ...
... Mo. The blood circulates through the body ... beginning to understand. Now, University of Missouri researcher ... and Blood Institute,s prestigious Method to Extend Research ... defining the signaling processes that control blood flow ...
... SpectraCell Laboratories, Inc.,announced that it has doubled ... a 20,000 sq. ft. building that was ... expansion added a second freestanding 20,000 sq.,ft. ... $3.5 million facility houses,SpectraCell,s state-of-the-art clinical laboratory ...
... offer ,Stem Cells 102, to present facts to ... issues surrounding the,safety and benefits of stem cell ... University of,Michigan experts are providing educational information to ... federal and state,oversight that apply to all human ...
... 27 The HealthCentral,Network, Inc. (http://www.HealthCentral.com ) ... business development for HealthCentral, has been,named President and ... a proven track record of growing young businesses, ... be responsible for,audience growth, user engagement, and revenue, ...
Cached Medicine News:Health News:Rheumatoid Arthritis a Threat to the Heart 2Health News:Rheumatoid Arthritis a Threat to the Heart 3Health News:Rheumatoid Arthritis a Threat to the Heart 4Health News:Better instructions reduce complications among patients using common blood thinner 2Health News:Better instructions reduce complications among patients using common blood thinner 3Health News:Researcher to provide new insight for treating vascular disease 2Health News:SpectraCell Laboratories Expands Operations in New Facility 2Health News:The Truth About Stem Cell Science 2Health News:The Truth About Stem Cell Science 3Health News:The Truth About Stem Cell Science 4Health News:The HealthCentral Network Names Jeremy Shane President and Chief Operating Officer 2Health News:The HealthCentral Network Names Jeremy Shane President and Chief Operating Officer 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: